Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Q3FY23 Quarterly Result Announced for Astec Lifesciences Ltd.

 Agrochemicals firm Astec Lifesciences announced Q3FY23 results: Consolidated Q3FY23: Company reported total income of Rs 121 crore in Q3FY23 as compared to Rs 175.3 crore in Q3FY22 Company reported EBITDA of Rs 15.9 crore in Q3FY23 as compared to Rs 44.8 crore in the same period last year, EBITDA margin stood at 13.2%. Consolidated 9MFY23: Total income increased to Rs 511.7 crore in 9MFY23 from Rs 408.2 crore in 9MFY22, a growth of 25.3% YoY. The company reported an EBITDA of Rs 81.3 crore in 9MFY23 as compared to Rs 92.3 crore in the same period last year, EBITDA margin stood at 15.9%. The company reported profit after tax of Rs 30.6 crore in 9MFY23 as compared to Rs 46.8 crore in the same period last year Commenting on the performance, Mr. N B Godrej, Chairman, Astec LifeSciences Limited, said: Q3FY23 was a challenging quarter for Astec’s enterprise business as our key products witnessed sluggish demand and lower realization in most of the markets. However, CMO sales grew by 2.8x YoY partly offsetting the decline in volumes from enterprise business. Result PDF
31-01-2023
Bigul

ASTEC LIFESCIENCES LIMITED - 533138 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 The Board of Directors of Astec LifeSciences Limited ('the Company'), at its Meeting held on Monday, 30th January, 2023, has approved the Unaudited Financial Results (both Standalone and Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Nine Months' period ended 31st December, 2022.
30-01-2023
Bigul

ASTEC LIFESCIENCES LIMITED - 533138 - Approval For Issuance Of Non-Convertible Debentures Upto An Amount Of Rs.50 Crore (Rupees Fifty Crore Only).

 The Board of Directors has approved the proposal to raise funds through issuance of Non-Convertible Debentures ('NCD') for expansion and development of business operations of the Company and meeting the short term and long-term financial requirements of the Company, including but not limited to, expenditure proposed to be incurred for improving the facilities being provided in its set-up and / or meeting the working capital requirements, for an amount upto Rs.50 Crore (Rupees Fifty Crore Only).
30-01-2023
Bigul

ASTEC LIFESCIENCES LIMITED - 533138 - Announcement under Regulation 30 (LODR)-Raising of Funds

 The Board of Directors has approved the proposal to raise funds through issuance of Non-Convertible Debentures ('NCD') for expansion and development of business operations of the Company and meeting the short term and long-term financial requirements of the Company, including but not limited to, expenditure proposed to be incurred for improving the facilities being provided in its set-up and / or meeting the working capital requirements, for an amount upto Rs.50 Crore (Rupees Fifty Crore Only).
30-01-2023
Bigul

ASTEC LIFESCIENCES LIMITED - 533138 - Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months'' Period Ended 31St December 2022 .

 Please find attached outcome of Board Meeting held today, 30th January 2023.
30-01-2023
Bigul

ASTEC LIFESCIENCES LIMITED - 533138 - Board Meeting Outcome for Outcome Of Board Meeting Held On 30Th January, 2023.

 Please find attached outcome of Board Meeting held on 30th January, 2023.
30-01-2023
Bigul

ASTEC LIFESCIENCES LIMITED - 533138 - Update on board meeting

 ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2023 ,inter alia, to consider and approve Further to the intimation dated 11th January, 2023 regarding the Meeting of the Board of Directors of Astec LifeSciences Limited ('the Company') scheduled to be held on Monday, 30th January, 2023 to, inter alia, consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and Nine Months' period ended 31st December, 2022, notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), that, at the said Meeting, the Board may also consider and approve issuance of Debentures or debt securities upto such limit as may be deemed appropriate and approved by the Board, subject to such other approval(s) as may be applicable.
25-01-2023
Bigul

ASTEC LIFESCIENCES LIMITED - 533138 - Board Meeting Intimation for The Approval Of The Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months' Period Ended 31St December, 2022

 ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2023 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Months' period ended 31st December, 2022 (subject to limited review by the Statutory Auditors of the Company), after these results are reviewed by the Audit Committee.
11-01-2023
Bigul

ASTEC LIFESCIENCES LIMITED - 533138 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find enclosed herewith, compliance certificate received from Bigshare Services Private Limited, Registrar and Share Transfer Agent of Astec LifeSciences Limited, for the Quarter ended 31st December, 2022, pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.
06-01-2023
Bigul

ASTEC LIFESCIENCES LIMITED - 533138 - Closure of Trading Window

 This is to inform you that as per the Company's Code of Conduct for Prohibition of Insider Trading, framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the securities of the Company will be closed with effect from Sunday, 1st January, 2023 till 48 (forty-eight) hours after the declaration of the Unaudited Financial Results of the Company for the Quarter and Nine Months' period ending 31st December, 2022. Accordingly, all Officers and Designated Employees (including Directors and Auditors) of the Company have been intimated not to trade (buy / sell) or otherwise deal in the Equity Shares of the Company during the stated period.
30-12-2022
Next Page
Close

Let's Open Free Demat Account